A number of sources have today confirmed the Therapeutic Goods Administration (TGA) has now approved the use of Harvoni as a prescription medicine in Australia. This is a necessary step before it can be listed on the Pharmaceutical Benefits Scheme (PBS), which the Australian Government is currently considering. 

The Pharmaceutical Benefits Advisory Commitee (PBAC) recently recommended to the Health Minister, Sussan Ley, that Harvoni (sofosbuvir + ledipasvir) and two other medicines used to treat and cure hepatitis C should be listed on the PBS. Once listed on the PBS the medicines would become affordable for Australians living with hepatitis C. Hepatitis Australia is monitoring developments regarding hepatitis C medicines and will continue to provide updates as information becomes available.

For more details, go to: http://www.hepatitisaustralia.com/newsarticles/a-step-closer-to-accessing-harvoni-as-tga-approves-use/12/5/2015